You are here

Roche

Roche's Ocrevus racks up more positive MS data in relapsing and primary progressive forms

Roche's Ocrevus racks up more positive MS data in relapsing and primary progressive forms

Fierce Pharma

multiple sclerosis

Flag link:

FDA says yes to rapid-acting Rituxan

FDA says yes to rapid-acting Rituxan

BioPharma Dive

refractory follicular lymphoma

diffuse large B-cell lymphoma

Flag link:

Novartis wins another biosimilar round with an OK for its Rituxan copycat

Novartis wins another biosimilar round with an OK for its Rituxan copycat

Endpoints

Flag link:

Pfizer, Roche and Aspen face South African probe into cancer drug prices

Pfizer, Roche and Aspen face South African probe into cancer drug prices

Reuters

Aspen Pharmacare

Flag link:

Roche ditches work on NewLink’s IDO cancer candidate

Roche ditches work on NewLink’s IDO cancer candidate

Fierce Biotech

NewLink Genetics

metastatic breast cancer

Flag link:

ASCO17: Roche's Alecensa bests Xalkori in lung study

ASCO17: Roche's Alecensa bests Xalkori in lung study

BioPharma Dive

Flag link:

Takeda, sporting a new-look portfolio, revs for Roche battle in ALK lung cancer

Takeda, sporting a new-look portfolio, revs for Roche battle in ALK lung cancer

Fierce Pharma

Flag link:

Novartis' Zykadia piles pressure on Pfizer's Xalkori, Roche's Alecensa with new lung cancer nod

Novartis' Zykadia piles pressure on Pfizer's Xalkori, Roche's Alecensa with new lung cancer nod

Fierce Pharma

non-small cell lung cancer

Flag link:

Prescribed Reading: FDA on a roll, while pharma continues sell off

Prescribed Reading: FDA on a roll, while pharma continues sell off

BioPharma Dive

Puma Biotechnology

Flag link:

Roche launches Accu-Chek Guide blood glucose meter

Roche launches Accu-Chek Guide blood glucose meter

Mass Device

blood glucose monitoring

Flag link:

Roche looks into PML report for Ocrevus patient

Roche looks into PML report for Ocrevus patient

BioPharma Dive

multiple sclerosis

Flag link:

Roche debuts latest blood glucose meter, savings program

Roche debuts latest blood glucose meter, savings program

Fierce Biotech

blood glucose monitoring

Flag link:

New Indication for Roche’s Actemra Means First FDA Approved Drug to Treat Giant Cell Arteritis

New Indication for Roche’s Actemra Means First FDA Approved Drug to Treat Giant Cell Arteritis

RAPS.org

giant cell arteritis

Flag link:

7 Areas to watch from the ASCO abstracts

7 Areas to watch from the ASCO abstracts

BioPharma Dive

NewLink Genetics

Juno Therapeutics

Flag link:

Merck’s checkpoint star Keytruda grabs another FDA OK, steering past wreckage of a Roche disaster

Merck’s checkpoint star Keytruda grabs another FDA OK, steering past wreckage of a Roche disaster

Endpoints

Flag link:

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

Endpoints

clinical trials

Flag link:

Amid sales growth, Roche plans defense from biosimilar threats

Amid sales growth, Roche plans defense from biosimilar threats

BioPharma Dive

Flag link:

Roche silently whisks away its $1.7B Seragon drug in a Q1 footnote

Roche silently whisks away its $1.7B Seragon drug in a Q1 footnote

Endpoints

Flag link:

Q1 Earnings Preview: AbbVie, AstraZeneca, BMS, Celgene, Roche, Sanofi

Q1 Earnings Preview: AbbVie, AstraZeneca, BMS, Celgene, Roche, Sanofi

BioPharma Dive

Bristol-Myers Squibb

Flag link:

Report: Price hikes are still driving pharma's earnings growth. Who's most at risk?

Report: Price hikes are still driving pharma's earnings growth. Who's most at risk?

Fierce Pharma

Bristol-Myers Squibb

Flag link: